Oppenheimer Maintains Fulcrum Therapeutics (FULC) Outperform Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on May 16, 2023, Oppenheimer maintained coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform recommendation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132012708-0d3f8f4b04c14405aa72e54940ab6a0e-3064dc565912458a94297c60b3d609e7.jpg "Is a Career in Investment Banking Worth It?")
:max_bytes(150000):strip_icc():format(jpeg)/KraftCadburyHostileTakeover-56143341d0004032a1cdb65ec3c2859b.jpg "What Are Some Top Examples of Hostile Takeovers?")
